The COMS is a multicenter randomized trial investigations - sponsored by The National Eye Institute and The National Cancer Institute - designed to evaluate therapeutic interventions for patients who have choroidal melanoma. The evaluations conducted in the COMS are aimed at determining which of two alternative therapies better prolongs the remaining lifetime of individuals diagnosed as having choroidal melanoma and, if two alternatives provide similar expectations of survival, to determine which offers the patient the longer cancer-free life and the better prognosis for vision overall.
Autor(es): Paul Montague, University of Iowa Ophthalmology. Originador(es): National Eye Institute., National Cancer Institute., National Eye Institute
Recurso adicionado em:
09/10/2002
Idiomas disponíveis:
Inglês